There is limited safety data available for non-cystic fibrosis patients; however, CFTR therapeutics have been shown to be well-tolerated in a small cohort of healthy volunteers (317) and smokers with chronic obstructive pulmonary disease (318). This evidence concerns the gene CFTR and cystic fibrosis.